UNSPSC 51311604: Setastine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C22H28ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6G3OCF528J, chemically known as 1h-azepine, 1-(2-(1-(4-chlorophenyl)-1-phenylethoxy)ethyl)hexahydro- but generally known as setastine, which bears US NIH Compound Identifier 43082. European Medicines Agency schedules Setastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10500MIG.

UNSPSC 51311604 Setastine, a Commodity code, covers the procurement of pharmaceutical products — specifically naloxone, drug deactivation systems, and generic multi-source pharmaceuticals with over-the-counter products — that state and local health agencies, county public-health departments, and cooperative purchasing alliances acquire to support community health initiatives, emergency response, and pharmacy benefit programs. State and local buyers under this code include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multi-state cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance), indicating that activity spans county-level health procurement, state-level pharmacy program administration, and regional cooperative contracting vehicles. The work involves fixed-price or discounted-pricing supply contracts with quarterly or routine deliveries, compliance with cGMP and Drug Supply Chain Security Act standards, and vendor relationships with authorized pharmaceutical wholesalers.

Recent activity appears concentrated in Florida and Texas, with multi-state cooperative procurement also active in Minnesota and Oregon. Seminole County, Florida issued an IFB for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through its e-Procurement Portal, with a response deadline of July 26, 2023, requiring quarterly delivery and electronic submission of unit-cost bids. The Texas Health and Human Services Commission posted an RFI on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription-fulfillment capabilities and vendor experience with self-insured health plans, signaling early-stage procurement planning for a Therapeutic Pharmacy Initiative. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP closing March 26, 2026 for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026 and evaluation weighted 75 percent on price competitiveness, requiring cGMP certification and DSCSA compliance.